A switching program that will see adult patients moved on to biosimilar versions of six biologics by 1 July 2020 has been unveiled by the Canadian province of Alberta.
Alberta Is Second Canadian Province To Switch To Biosimilars
Follows British Columbia Switching Program That Began This Year
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

More from Biosimilars
More from Products
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.